NCT01463891 2023-07-24
Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer (Study HAL01S)
Eisai Inc.
Completed
Clinical Trials
6 trialsNCT03027245 2022-07-13
IRENE
Eisai Inc.
Completed
NCT02551263 2021-06-11
E-SPEC
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Completed
NCT03058406 2020-04-06
HAL03T
Eisai Inc.
Completed
NCT02393287 2019-05-09
ReProLine
Institut Cancerologie de l'Ouest
Completed
NCT03437083 2019-01-25
A Study to Investigate the Efficacy and Safety of Eribulin in Korean Breast Cancer Participants
Eisai Inc.
Completed